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Introduction
Ischemic heart disease is the leading cause of death in 
developed countries [1]. While survival has improved 
following a myocardial infarction, signiﬁ  cant, irreversible 
loss of myocardial tissue often leads to congestive heart 
failure, ventricular arrhythmias and increased disability. 
It is estimated that 5 million people in the USA are 
aﬀ  ected by heart failure, with 60% of cases attributed to 
ischemic heart disease, at a cost of $35 billion per year to 
society [2,3]. Because the reproductive capacity of cardio-
myocytes is limited, cellular cardiomyoplasty, deﬁ  ned as 
the delivery of donor stem or progenitor cells into the 
myocardium with the goal of improving cardiac function, 
is a potential approach to replace damaged or dead 
myocytes and improve cardiac function. To date, a large 
number of clinical studies have examined the potential 
therapeutic eﬀ  ects of myocardial stem cell therapy [4-7]. 
Th   is review aims to provide an overview of the modes of 
delivery of bone-marrow-derived stem/progenitor cells 
to the myocardium, with particular reference to percu-
taneous routes of delivery after a myocardial infarction.
Bone marrow cells
Various cell types have been tested experimentally for 
cardiac repair and include bone-marrow-derived cells 
(BMCs), skeletal myoblasts, placental/cord-blood-derived 
cells, adipose-tissue-derived cells, resident cardiac 
progenitor cells, embryonic stem cells and, recently, 
induced pluripotent stem cells [8,9]. Because of the ease 
of isolation and expansion and the avoidance of allo-
geneic incompatibility issues, BMCs and skeletal myo-
blasts of autologous origin have been the major cell types 
evaluated in clinical trials.
BMCs are a heterogeneous population of cells consist-
ing of approximately 98% diﬀ  erentiated cells and approxi-
mately 2% stem or progenitor cells, which include 
hematopoietic stem cells, endothelial progenitor cells and 
mesenchymal stem cells (MSCs). Bone-marrow-derived 
stem or progenitor cells have been demonstrated to be 
able to trans-diﬀ  erentiate into various cell types of the 
body, including cardiomyocytes [10-12]. Like skeletal 
myoblasts, BMCs can be readily harvested from patients 
and expanded ex vivo for autologous transplantation, and 
BMC transplantation in ischemic animal models has 
resulted in improvement in cardiac function [13,14]. 
Mechanistically, paracrine eﬀ  ects promoting neoangio-
genesis have been the major purported mechanism 
responsible for clinical improvements in cardiac function 
indices [15-18].
Cell delivery modes
Optimal cell therapy depends on successful delivery into 
the myocardial area of need, engraftment of a suﬃ   cient 
concentration of cells and prolonged survival of the 
transplanted cells. While cells have been delivered and a 
biological eﬀ  ect has been observed, the optimal stem/
precursor cell to use, the number of cells required, the 
timing of transplantation post-infarction, and the optimal 
cellular milieu and delivery route have yet to be 
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number of routes: intravenous, intracoronary, intramyo-
cardial, and intrapericardial. Few studies have compared 
these approaches (to be discussed below) and questions 
remain regarding the optimal approach.
Intravenous delivery
Th  e intravenous technique, through either a peripheral 
or central venous catheter, is the simplest delivery mode 
and avoids the risk of an invasive procedure. However, it 
is the least eﬃ     cacious delivery method since a high 
percentage of infused cells may become sequestered in 
the lung, liver, spleen or other organs, allowing only a 
small number of cells to actually enter the coronary 
circulation, where they must still transverse the arterial 
or capillary wall [19]. Moreover, this route is not amenable 
for patients with occluded arteries, unless there are 
suﬃ   cient routes of collateral coronary artery circulation.
Intracoronary delivery
Selective intracoronary cell delivery involves cell infusion, 
generally through the central lumen of a balloon catheter 
positioned in the coronary artery. Cells can be injected 
while either maintaining coronary ﬂ   ow or following 
interruption of ﬂ  ow with balloon occlusion to minimize 
rapid cell washout. An intracoronary approach allows for 
selective delivery of cells to the myocardial area of 
interest (Figure 1) and theoretically limits risks of sys-
temic administration. Indeed, delivery is more concen-
trated in ischemic and border zone regions (Figure 2). 
Coronary delivery requires that the target myocardium 
be subtended by a patent coronary artery or identiﬁ  able 
collateral vessel and so is performed following percu-
taneous coronary intervention (PCI). Intracoronary 
infusion has been used in patients with ST-segment 
elevation myocardial infarction or chronic myocardial 
ischemia [20]. With any transvascular delivery approach, 
cell retention ultimately requires transendothelial 
passage and migration into the myocardium.
Intramyocardial delivery
Cells can be injected directly into the myocardium via a 
transepicardial or transendocardial injection. Such direct 
injection techniques have been used in patients present-
ing with an ischemic cardiomyopathy when an occluded 
coronary artery limits transvascular cell delivery, often as 
an adjunct during coronary artery bypass grafting. While 
an epicardial approach allows for direct visualization of 
the infarcted myocardium for accurate targeting of cell 
injections, it requires open-heart surgery with its 
attendant risks.
Targeted injections can also be obtained by an 
endocardial approach, which obviates the need for 
surgery and has been applied as a stand-alone procedure. 
Th  e lack of direct visualization with the endocardial 
approach has led to the development of specialized 
catheters that utilize electromechanical mapping systems 
for the identiﬁ  cation of areas of interest, such as hibernat-
ing or infarcted tissue or tissue on the border zone of 
Figure 1. One hour after reperfusion following a myocardial 
infarction 4.1 × 107 mesenchymal stem cells labeled with 
iron nanoparticles were delivered into the mid left anterior 
descending coronary artery of pigs. (a-d) Sagittal (a,b) and 
transverse (c,d) views from a post-mortem high-resolution magnetic 
resonance imaging scan show increased concentrations of iron 
particles within the mid wall (c) and distal septal (sept) and anterior 
(ant) walls (d). Lat, lateral wall; post, posterior.
Figure 2. Using the pig model, intracoronary delivery of 
mesenchymal stem cells containing fl  uorescent and iron 
nanoparticles following myocardial infarction and reperfusion 
results in substantially more cells deposited in the infarcted 
and border zones. The total numbers of cells for each section are 
shown as gray bars. No cells were retrieved in non-infarct tissue 
(control). The actual number is the cell number retrieved from 
the obtained samples and the theoretical scaled number was 
extrapolated to refl  ect the total border zone and infarcted myocardial 
volume. Approximately 65% of the delivered cells were recovered 
immediately after delivery. Error bars indicate standard deviation.
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limitation of both epicardial and endocardial approaches 
is the risk of perforation.
Retrograde coronary sinus delivery
An emerging intravenous mode via a retrograde coronary 
sinus delivery approach may prove eﬃ   cacious  [22]. 
Following catheter placement into the coronary sinus, a 
balloon infusion catheter is placed, the balloon inﬂ  ated 
and cells administered by infusion at pressures 20 ml 
higher than the coronary sinus pressure, allowing for 
retrograde perfusion of cells into the myocardium. Th  e 
percutaneous retrograde coronary sinus delivery method 
has been well studied in the delivery of proteins and 
genes in preclinical models and appears to provide for 
more homogenous delivery across the myocardium [23]. 
Like intracoronary delivery, cells must transverse the 
vessel wall.
Intrapericardial delivery
Intrapericardial delivery of cells is the least studied delivery 
approach. An advantage of a pericardial approach is that a 
large number of cells can be deposited and retained with 
the potential for enhanced bioavailability of infused cells. 
However, migration of cells across the visceral 
pericardium into the myocardium is necessary. Small 
preclinical studies suggest that such delivered BMCs 
home to the infarct site [24]. Little is known about the 
eﬃ   ciency and eﬃ   cacy of cells delivered via this approach 
and future studies will be needed to clarify its usefulness.
Comparison of delivery methods
Currently no delivery strategy has emerged as the most 
optimal administration route for cellular cardiomyoplasty 
and to date there are no head to head clinical compari-
sons of the diﬀ  erent delivery routes. Large animal models 
have been useful in this regard. Immediately following 
delivery of peripheral blood mononuclear cells 6 days 
after myocardial infarction, more cells are observed in 
the myocardium after intramyocardial (11 ± 3%) com-
pared to intracoronary (2.6 ± 0.3%) or retrograde coronary 
venous delivery (3.2 ± 1%). All three approaches, however, 
resulted in a signiﬁ  cant fraction of cells entering into the 
pulmonary circulation (intracoronary, 47 ± 1%; intra-
myo  cardial, 26 ± 3%; retrograde, 43 ± 3%) [25]. Freyman 
and colleagues [26] published data comparing intra-
venous, intracoronary, and endocardial delivery of MSCs 
immediately following infarction in a porcine model. 
Cellular engraftment was ascertained 14 days later in 
order to solely evaluate the short-term retention and 
engraftment of cells. Intracoronary delivery of MSCs was 
associated with a signiﬁ   cantly greater number of 
engrafted MSCs compared to either percutaneous endo-
cardial delivery or intravenous delivery. However, in all 
three groups the percentage of retained/engrafted cells 
was low (intravenous, 0%; intracoronary, 6%; endocardial, 
3%). Whereas endocardial delivery was safe and well 
tolerated, intracoronary delivery was associated in almost 
half of the deliveries with a higher incidence of decreased 
distal coronary blood ﬂ   ow. Histologic evaluation 
demonstrated plugging of capillaries and arterials in the 
infarcted area due to the MSCs in association with red 
blood cells and neutrophils. Endocardial delivery was 
associated with decreased cell engraftment in the 
pulmonary tissue while the intravenous approach, not 
surprisingly, was associated with the highest pulmonary 
engraftment rate.
Follow-up studies have evaluated the eﬀ  ect  of 
intracoronary perfusion protocols on subsequent coro-
nary blood ﬂ  ow in the infarcted pig model [27]. Th  ree 
protocols were evaluated: ﬁ  ve serial 2-ml infusions, with 
the balloon inﬂ  ated for 2 minutes, followed by 2 minutes 
of reperfusion; a single 10-ml infusion, with the balloon 
inﬂ  ated, over 10 seconds (60 ml/minute); and a single 
10-ml infusion over 30 seconds (20 ml/minute). Th  e 
results showed that serial infusions were associated with 
substantially decreased distal blood ﬂ  ow.  Persistent 
decreased blood ﬂ  ow was noted at 14 days in half the 
animals in the serial infusion group and only 17% of those 
in the single infusion groups. Th  e decreased distal 
coronary blood ﬂ  ow was associated with a signiﬁ  cantly 
increased mortality rate in the serial infusion animals. 
Th   ese observations correlate with what is known 
clinically: that no reﬂ  ow (following PCI) is a predictor of 
poor outcomes [28]. Others have also shown extensive 
plugging of the microvasculature following delivery of 
MSCs using serial infusions in a canine model 7 days 
after infarction [29]. In that study an association between 
increased velocity of intracoronary infusion and micro-
infarcts in non-infarcted dogs was observed. Vulliet and 
colleagues [30] observed that the delivery of 
mesenchymal stromal cells in healthy, non-infarcted dogs 
caused electrocardio  graphic ST changes, microvascular 
plugging and micro  infarcts. Taken together, these data 
suggest that either eliminating sequential balloon 
inﬂ  ations and/or increas  ing the time between myocardial 
reperfusion and intracoronary delivery may be necessary 
to reduce no-reﬂ  ow.
Th  e association of bone-marrow-derived stem cells 
with subsequent decreased distal blood ﬂ  ow has not been 
observed in humans, which may reﬂ   ect the increased 
time between infarction and cell delivery in humans 
compared to animals [31-35]. In the initial clinical 
demonstration of intracoronary BMC delivery into the 
necrotic zone there were no complications or side-eﬀ  ects 
(although the possible complications were not listed) in 
10 patients infused 5 to 9 days after onset of infarction 
with 1.5 × 106 to 4 × 106 mononuclear cells [34]. Timing 
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clinical studies, delivery of cells occurs 1 to 8 days after 
infarction, while in pre-clinical studies injection often 
occurs immediately following infarction. Th   is delay may 
allow for a more complete recovery of microvascular 
function and a reduction in the interstitial edema that 
occurs following recanalization of an infarct-related 
artery, both of which are likely to impede successful cell 
engraftment [31,36]. Also, it should be noted that MSCs 
are relatively large cells (10 to 20 μm) and the future use 
of smaller cells may be less likely to cause microvascular 
plugging and decreased distal blood ﬂ  ow.
Intracoronary cell therapy in patients
Th  e ease and safety of catheter-based interventions in 
patients with acute and chronic ischemic heart disease 
has made the intracoronary cell delivery approach the 
clinical method of choice. A common feature of many pre-
clinical and early clinical studies involving cellular cardio-
myoplasty is the short-term beneﬁ  t in terms of improve-
ment in one or more endpoints: ejection fraction, 
ventricular volumes, infarct size and myocardial perfusion.
In the BOOST trial (BOne marrOw transfer to enhance 
ST-elevation infarct regeneration) [32], 60 patients were 
randomly assigned to standard therapy versus 2.4 × 109 
nucleated BMC transfer via intracoronary delivery an 
average of 4.8 days after primary PCI. Cardiac function 
was assessed with magnetic resonance imaging (MRI) 
prior to and 6, 18, and 61 months after cell transfer. Th  e 
results showed short-term improvement in left ventri-
cular contractility within the infarct border zone and a 
6% improvement of global left ventricular ejection 
fraction at 6 months in the experimental group compared 
to the control group. However, the improvement was not 
observed at either 18 or 61 months.
Th  e Leuven acute myocardial infarction (AMI) trial 
enrolled 67 patients randomly assigned to receive 
4.8  ×  108 mononucleated BMCs or placebo within 
24  hours of primary PCI [31]. MRI assessment of left 
ventricular ejection fraction at 3 to 4 days and 4 months 
did not demonstrate an improvement with cell therapy. 
However, there was a greater reduction in infarct volume 
after 4 months, assessed by serial MRI in the cell therapy 
group with improvement in regional contractility. In the 
REPAIR-AMI trial (REinfusion of enriched Progenitor 
cells And Infarct Remodeling in Acute Myocardial 
Infarction), 187 patients were randomly assigned to 
receive placebo or 2.4 × 108 mononucleated BMCs at a 
mean of 4.4 days after primary PCI [37]. Ventricular 
function was found to improve by an average of 2.5% as 
assessed by contrast angiography at 4-month follow-up 
when compared to controls.
In the FINCELL (FINnish stem CELL study) trial, 80 
patients with an AMI initially treated with thrombolytic 
therapy followed by PCI were randomized to either 
placebo or cell therapy with 3.6 × 109 mononucleated 
BMCs via the intracoronary delivery approach [38]. Cells 
were infused immediately after PCI, which was per  formed 
2 to 6 days after thombolysis. Follow-up at 6  months 
signiﬁ   cantly demonstrated an improved left ventricular 
ejection fraction of 5% compared with the control group. 
Th  e REGENT trial (myocardial REGENeraT  by intra-
coronary infusion of selected population of stem cells in 
acute myocardial infarction) examined 200 patients with 
anterior wall acute myo  cardial infarctions, randomizing 
patients to either placebo or intracoronary infusion of 
1.7 × 108 unselected mono  nucleated BMCs or 1.9 × 106 
enriched CXRR4+CD34+ progenitor mono  nucleated 
BMCs 7 days, on average, following primary PCI [39]. 
Left ventricular function assessed by MRI at 6-month 
follow-up demonstrated a 3% improvement in ejection 
fraction in the cell-therapy-treated group versus control, 
suggesting that bone marrow populations contain  ing 
progenitor cell surface markers could be responsible for 
the observed eﬀ  ects.
Th  e largest trial involving intracoronary delivery for 
chronic ischemic heart disease was TOPCARE-CHD 
(Transplantation Of Progenitor Cells And Regeneration 
Enhancement in Chronic ischemic Heart Disease), which 
enrolled 75 patients with ischemic heart failure [40]. 
Patients were randomized to receive placebo or a cell 
intracoronary cell infusion of 2.0 × 108 mononucleated 
BMCs or circulating blood-derived progenitor cells into 
the patent coronary artery supplying the most dyskinetic 
left ventricular area. At 3-month follow-up, left 
ventricular function, assessed by contrast angiography, 
was improved by 2.9% in patients receiving the BMCs 
versus patients receiving either circulating blood-derived 
progenitor cells or placebo.
Unresolved issues regarding intracoronary 
delivery
It is estimated that following a typical myocardial infarc-
tion one billion or more cardiomyocytes are lost [41]. 
Replacing even a fraction of the lost cells is challenging. 
Th  e results from the largest ﬁ   rst generation clinical 
studies examining the beneﬁ   t of stem/progenitor cell 
therapy delivered via the intracoronary route suggests 
that cell transplantation results in a mild short-term 
improvement in left ventricular function. More recent 
data from Yousef and colleagues [42] demonstrated 
signiﬁ  cant clinical beneﬁ  t and decreased mortality up to 
5 years after BMC infusion. Th  ese results should be 
viewed as preliminary as the studies were relatively small 
in size, and it is unresolved whether these mild 
improvements in left ventricular function will translate 
into sustained clinical improvements in morbidity and 
mortality.
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not been determined nor whether intracoronary delivery 
is the optimal delivery route. Unfortunately, the early 
excitement demonstrating the promise of regenerative 
cell therapy has led to design and implementation of 
multiple clinical trials examining the eﬃ   cacy of cellular 
cardiomyoplasty in the absence of data regarding the 
most eﬃ     cacious stem or progenitor cell, optimal cell 
isolation protocols, dose of delivered cells, timing of 
delivery, location of delivery (normal myocardium, 
ischemic border zone [43] or infarcted zone), method of 
delivery, and methods to evaluate outcome and determi-
nation of the proper endpoint. Indeed, even in animal 
models the diagnostic approaches to determine engraft-
ment and tracking of cells are not optimal and may falsely 
overestimate cellular engraftment and survival [44]. As 
such, it has proven diﬃ   cult to compare results from the 
various trials or pre-clinical studies. Furthermore, the 
mechanism by which stem cell delivery improves regional 
wall motion is incompletely under  stood. Several pre-
clinical studies in large animal models have demonstrated 
poor retention and survival of delivered cells within the 
area of interest/delivery and so a paracrine eﬀ  ect by the 
infused cells on neighboring cells has been postulated. To 
date, this paracrine eﬀ  ect has not been clearly elucidated.
For patients presenting with an AMI, the ease of 
delivery following catheter intervention to re-establish 
coronary ﬂ  ow certainly makes the intracoronary delivery 
approach appealing. Future trials will need to establish 
the optimal timing for delivery following myocardial 
infarction to maximally aﬀ  ect clinical outcomes. Dose 
ranging studies to determine the most eﬃ   cacious dose 
for intracoronary delivery will also need to be performed. 
In studies evaluating intramyocardial delivery in a 
porcine model of infarction, a dose-response eﬀ  ect was 
not demonstrated [45]. Likewise, in human clinical trials 
using an intracoronary delivery approach no correlation 
between infused cell number and infarct size reduction 
or improvement in ejection fraction has been observed 
[42].
While preclinical animal studies suggest that by 
optimizing delivery pressures and duration using a single 
infusion at 20 ml/minute results in similar engraftment, 
improved blood ﬂ  ow and decreased mortality, optimal 
delivery pressures and duration for human intracoronary 
delivery are not currently known [27]. Also, successful 
intra  coronary delivery of cells is dependent upon trans-
endothelial passage and migration into the myocardium. 
Th   e observed poor engraftment rates are likely a 
reﬂ  ection of the poor eﬃ   ciency of this process and poor 
cell survival rates, highlighting the importance of the 
cellular milieu that favors these events.
Pre-clinical and clinical investigations to determine 
cellular or biochemical factors to enhance the eﬃ   ciency 
of these processes will likely result in improved cell 
engraftment. One approach to improve cellular engraft-
ment may be to align the stromal cell-derived factor 
(SDF)-1/chemokine receptor 4 (CXCR4) axis [46]. SDF-1 
is a CXC chemokine constitutively produced by bone 
marrow cells and the interaction of SDF-1 and its 
receptor CXCR4 may be of critical importance in cellular 
engraftment of BMCs within ischemic myocardium [47]. 
In the setting of ischemia both SDF-1 and CXCR4 are 
upregulated [48]. Recruitment and engraftment of BMCs 
is thereby enhanced. However, SDF-1 expression in the 
myocardium increases early after infarction, declining 4 
to 7 days after infarction, while cellular expression of 
CXCR4 [47] occurs in mature BMCs, thereby taking days 
to achieve expression levels high enough to improve 
engraftment. Hence, there may be a SDF-1a/CXCR4 mal-
alignment within ischemic myocardium that precludes 
adequate BMC engraftment. By aligning temporally the 
SDF-1/CXCR4 axis it may be possible to increase 
myocardial BMC engraftment. Finally, if the ‘paracrine 
eﬀ  ect’ appears to be a major mechanism of beneﬁ  t, it 
needs to be further investigated. Hopefully, improvement 
in these areas will lead to greater cell engraftment, 
greater improvement in myocardial function and better 
clinical outcomes.
Conclusion
If successful, BMC delivery to the infarcted or chronically 
ischemic patient has the potential to reduce mortality 
rates and clinical symptoms. Indeed, the hope is to 
reduce progression to congestive heart failure and the 
incidence of ventricular arrhythmias resulting from large 
myocardial infarctions. It could be possible that delivery 
of a relatively small concentration of stem cells to the 
arrhythmogenic focus could reduce the likelihood of 
recurrent life-threatening ventricular tachycardia. Th  e 
possibilities are great but the important and more 
scientiﬁ  cally boring questions examining fundamentals 
of myocardial delivery and optimization of stem cells 
need to be answered. As a result, there is a risk that the 
promise inherent in this approach may never be 
actualized.
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